ONC – BeOne Medicines Ltd ADR

ONC — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

1.49

Margin Of Safety %

Put/Call OI Ratio

1.43

EPS Next Q Diff

0.75

EPS Last/This Y

-2.59

EPS This/Next Y

3.83

Price

282.2

Target Price

410.21

Analyst Recom

1.26

Performance Q

-9.21

Upside

-68.8%

Beta

0.57

Ticker: ONC

14 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	ONC	302.22	1.86	0.00	3042
2026-03-10	ONC	305.32	1.87	9.00	3037
2026-03-11	ONC	299.08	1.88	0.68	3047
2026-03-12	ONC	285.45	1.70	3.50	3176
2026-03-13	ONC	285.3	1.70	3.50	3176
2026-03-17	ONC	287.13	1.70	999.99	3186
2026-03-18	ONC	282.41	1.69	2.25	3176
2026-03-19	ONC	282.93	1.69	0.40	3170
2026-03-20	ONC	275.29	1.40	0.73	3406
2026-03-23	ONC	274.47	1.52	0.12	3182
2026-03-24	ONC	275.66	1.48	2.00	3209
2026-03-25	ONC	283.51	1.47	0.13	3203
2026-03-26	ONC	277.13	1.45	0.25	3235
2026-03-27	ONC	282.5	1.43	1.22	3252
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

14 items 1 of 1

14 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	ONC	302.50	7640.0	618.0	5.50
2026-03-10	ONC	304.75	7640.0	344.4	5.50
2026-03-11	ONC	300.28	7640.0	307.0	5.50
2026-03-12	ONC	287.06	7640.0	290.6	5.50
2026-03-13	ONC	283.51	7640.0	292.8	5.50
2026-03-17	ONC	287.25	7640.0	312.1	5.50
2026-03-18	ONC	282.50	7640.0	302.4	5.50
2026-03-19	ONC	282.86	8070.0	318.3	5.47
2026-03-20	ONC	276.08	8070.0	323.0	5.47
2026-03-23	ONC	275.46	8070.0	326.5	5.47
2026-03-24	ONC	275.83	8070.0	368.4	5.47
2026-03-25	ONC	282.94	8070.0	317.9	5.47
2026-03-26	ONC	276.48	8070.0	294.4	5.47
2026-03-27	ONC	282.20	8070.0	328.5	5.47
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

14 items 1 of 1

14 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	ONC	-24.80	0.60	1.40
2026-03-10	ONC	-24.52	0.60	1.40
2026-03-11	ONC	-24.52	0.60	1.35
2026-03-12	ONC	-24.01	0.60	1.35
2026-03-13	ONC	-22.99	0.60	1.35
2026-03-17	ONC	-22.99	0.72	1.35
2026-03-18	ONC	-22.99	0.72	1.35
2026-03-19	ONC	-19.89	0.72	1.35
2026-03-20	ONC	-19.89	0.72	1.35
2026-03-23	ONC	-19.89	0.62	1.47
2026-03-24	ONC	-21.25	0.62	1.47
2026-03-25	ONC	-21.25	0.62	1.49
2026-03-26	ONC	-21.25	0.62	1.49
2026-03-27	ONC	-21.25	0.62	1.49
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

14 items 1 of 1

Last Quarter Act. EPS

0.58

Avg. EPS Est. Current Quarter

0.82

Avg. EPS Est. Next Quarter

1.33

Insider Transactions

-21.25

Institutional Transactions

0.62

Beta

0.57

Average Sales Estimate Current Quarter

1437

Average Sales Estimate Next Quarter

1566

Fair Value

298.86

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

33.8

Max Drawdown 5-Year %

-70

Target Price

410.21

P/E

112.18

Forward P/E

29.65

PEG

0.42

P/S

5.39

P/B

7.19

P/Free Cash Flow

30.58

EPS

2.52

Average EPS Est. Cur. Y

5.47

EPS Next Y. (Est.)

9.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

5.37

Relative Volume

0.85

Return on Equity vs Sector %

-20.8

Return on Equity vs Industry %

-4.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.79

EBIT Estimation

328.5

◆ ONC Healthcare

$283.03

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

18/25

Volume

7/15

Valuation

18/20

TP/AR

2/10

Options

2/10

RSI

38.7

Range 1M

26.3%

Sup Dist

3.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

25/30

Estimates

5/20

Inst/Vol

4/15

Options

3/10

EPS Yr

131.1%

EPS NY

57.1%

52W%

45.8%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +18.2% upside

Quality

10/30

Valuation

9/30

Growth

17/25

Stability

6/10

LT Trend

0/5

Upside

+18.2%

Quality

MoS

BeOne Medicines Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 12000

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

ONC

Latest News

—

Caricamento notizie per ONC…

stock quote shares ONC – BeOne Medicines Ltd ADR Stock Price stock today

news today ONC – BeOne Medicines Ltd ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch ONC – BeOne Medicines Ltd ADR yahoo finance google finance

stock history ONC – BeOne Medicines Ltd ADR invest stock market

stock prices ONC premarket after hours

ticker ONC fair value insiders trading

AMRZ – Amrize Ltd

AMRZ — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

1.28

Margin Of Safety %

Put/Call OI Ratio

0.6

EPS Next Q Diff

0.33

EPS Last/This Y

0.55

EPS This/Next Y

0.44

Price

53.8

Target Price

66.97

Analyst Recom

Performance Q

-3.71

Upside

-12.5%

Beta

Ticker: AMRZ

14 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	AMRZ	58.89	0.70	0.91	31140
2026-03-10	AMRZ	59.19	0.71	0.08	31440
2026-03-11	AMRZ	58.25	0.70	0.02	31547
2026-03-12	AMRZ	56.3	0.78	0.25	29878
2026-03-13	AMRZ	56.3	0.78	0.27	29878
2026-03-17	AMRZ	56.41	0.73	0.06	31730
2026-03-18	AMRZ	54.64	0.68	0.49	33198
2026-03-19	AMRZ	54.18	0.68	0.11	33596
2026-03-20	AMRZ	52.56	0.66	4.10	33926
2026-03-23	AMRZ	55.28	0.81	0.08	31278
2026-03-24	AMRZ	55.32	0.80	0.11	31417
2026-03-25	AMRZ	56.11	0.80	0.11	31499
2026-03-26	AMRZ	55.22	0.79	19.86	31662
2026-03-27	AMRZ	53.82	0.60	0.42	28172
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

14 items 1 of 1

14 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	AMRZ	58.91	-	422.2	-
2026-03-10	AMRZ	59.17	-	484.1	-
2026-03-11	AMRZ	58.21	-	356.6	-
2026-03-12	AMRZ	56.30	-	328.9	-
2026-03-13	AMRZ	55.55	-	335.9	2.69
2026-03-17	AMRZ	56.42	-	437.4	2.69
2026-03-18	AMRZ	54.65	-	341.9	2.69
2026-03-19	AMRZ	54.14	-	305.4	2.69
2026-03-20	AMRZ	52.56	-	350.5	2.69
2026-03-23	AMRZ	55.26	-	463.3	2.69
2026-03-24	AMRZ	55.31	-	396.9	2.69
2026-03-25	AMRZ	56.12	-	391.4	2.69
2026-03-26	AMRZ	55.20	-	350.9	2.69
2026-03-27	AMRZ	53.80	-	317.6	2.69
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

14 items 1 of 1

14 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	AMRZ	0.30	1.05	2.03
2026-03-10	AMRZ	0.31	1.05	2.03
2026-03-11	AMRZ	0.32	1.05	1.63
2026-03-12	AMRZ	0.32	1.05	1.63
2026-03-13	AMRZ	0.32	1.05	1.63
2026-03-17	AMRZ	0.33	1.06	1.63
2026-03-18	AMRZ	0.33	1.06	1.63
2026-03-19	AMRZ	0.33	1.06	1.63
2026-03-20	AMRZ	0.33	1.06	1.63
2026-03-23	AMRZ	0.33	1.64	1.63
2026-03-24	AMRZ	0.33	1.64	1.63
2026-03-25	AMRZ	0.33	1.64	1.28
2026-03-26	AMRZ	0.33	1.64	1.28
2026-03-27	AMRZ	0.33	1.64	1.28
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

14 items 1 of 1

Last Quarter Act. EPS

0.62

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

0.95

Insider Transactions

0.33

Institutional Transactions

1.64

Beta

Average Sales Estimate Current Quarter

2147

Average Sales Estimate Next Quarter

3356

Fair Value

58.74

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

18.4

Max Drawdown 5-Year %

Target Price

66.97

P/E

25.1

Forward P/E

16.77

PEG

0.85

P/S

2.52

P/B

2.24

P/Free Cash Flow

20.93

EPS

2.14

Average EPS Est. Cur. Y

2.69

EPS Next Y. (Est.)

3.13

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

10.03

Relative Volume

0.52

Return on Equity vs Sector %

-6.4

Return on Equity vs Industry %

-13.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

317.6

◆ AMRZ Basic Materials

$53.78

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

16/20

Pullback

13/25

Volume

11/15

Valuation

14/20

TP/AR

1/10

Options

5/10

RSI

39.4

Range 1M

14.8%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

13/25

Growth

15/30

Estimates

2/20

Inst/Vol

3/15

Options

7/10

EPS Yr

31.6%

EPS NY

13.9%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +21.7% upside

Quality

7/30

Valuation

10/30

Growth

14/25

Stability

5/10

LT Trend

1/5

Upside

+21.7%

Quality

MoS

Amrize Ltd

Sector: Basic Materials

Industry: Building Materials

Employees: 19000

Amrize AG engages in the provision of various building solutions for infrastructure, commercial, and residential construction markets in North America. It operates through two segments, Building Materials and Building Envelope. The Building Materials segment offers cement and aggregates, as well as ready-mix concrete, asphalt, and other construction materials. The Building Envelope segment provides advanced roofing and wall systems, including single-ply membranes, insulation, shingles, sheathing, waterproofing, and protective coatings; and adhesives, tapes, and sealants. The company was formerly known as Holcim North America Finance Ltd and changed its name to Amrize AG in December 2013. Amrize AG was incorporated in 2023 and is based in Zug, Switzerland.

AMRZ

Latest News

—

Caricamento notizie per AMRZ…

stock quote shares AMRZ – Amrize Ltd Stock Price stock today

news today AMRZ – Amrize Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch AMRZ – Amrize Ltd yahoo finance google finance

stock history AMRZ – Amrize Ltd invest stock market

stock prices AMRZ premarket after hours

ticker AMRZ fair value insiders trading

ADCT – Adc Therapeutics SA

ADCT — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

4.63

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

-0.16

EPS Last/This Y

0.31

EPS This/Next Y

0.17

Price

3.71

Target Price

8.2

Analyst Recom

Performance Q

4.96

Upside

-1,235.1%

Beta

1.91

Ticker: ADCT

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-02-27	ADCT	4.1	0.06	1.04	1958
2026-03-03	ADCT	4.06	0.08	0.00	2314
2026-03-04	ADCT	4.25	0.07	0.00	2503
2026-03-06	ADCT	4.1	0.07	0.00	2595
2026-03-09	ADCT	4.23	0.07	0.00	2669
2026-03-10	ADCT	4.8	0.07	0.00	2661
2026-03-11	ADCT	4.88	0.06	0.00	2750
2026-03-12	ADCT	4.35	0.06	0.27	2752
2026-03-13	ADCT	4.35	0.06	0.14	2752
2026-03-17	ADCT	4.11	0.06	0.00	3189
2026-03-18	ADCT	4.01	0.06	0.00	3070
2026-03-20	ADCT	3.88	0.06	0.13	3212
2026-03-25	ADCT	3.97	0.04	0.00	2794
2026-03-26	ADCT	3.96	0.04	0.00	2815
2026-03-27	ADCT	3.7	0.04	0.00	2873
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-02-27	ADCT	4.10	-	-	-1.41
2026-03-02	ADCT	4.18	-	-	-1.41
2026-03-03	ADCT	4.06	-	-	-1.41
2026-03-04	ADCT	4.25	-	-	-1.41
2026-03-05	ADCT	4.19	-	-	-1.41
2026-03-06	ADCT	4.11	-	-	-1.41
2026-03-09	ADCT	4.23	-	-	-1.41
2026-03-10	ADCT	4.79	-	-	-1.41
2026-03-11	ADCT	4.89	-	-	-1.41
2026-03-12	ADCT	4.34	-	-	-0.81
2026-03-13	ADCT	4.13	-	-	-0.81
2026-03-17	ADCT	4.10	-	-	-0.81
2026-03-18	ADCT	4.01	-	-	-0.81
2026-03-19	ADCT	4.02	-	-	-0.81
2026-03-20	ADCT	3.87	-	-	-0.81
2026-03-23	ADCT	4.05	-	-	-0.81
2026-03-24	ADCT	3.94	-	-	-0.81
2026-03-25	ADCT	3.98	-	-	-0.81
2026-03-26	ADCT	3.94	-	-	-0.81
2026-03-27	ADCT	3.71	-	-	-0.81
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-02-27	ADCT	0.00	2.64	4.83
2026-03-02	ADCT	0.00	2.89	4.83
2026-03-03	ADCT	0.00	2.89	4.83
2026-03-04	ADCT	0.00	2.89	4.83
2026-03-05	ADCT	0.00	2.89	4.83
2026-03-06	ADCT	0.00	2.89	4.83
2026-03-09	ADCT	0.00	3.63	4.83
2026-03-10	ADCT	0.00	3.63	4.83
2026-03-11	ADCT	0.00	3.63	4.54
2026-03-12	ADCT	0.00	3.63	4.54
2026-03-13	ADCT	0.00	3.63	4.43
2026-03-18	ADCT	0.00	3.61	4.43
2026-03-19	ADCT	0.00	3.61	4.43
2026-03-20	ADCT	0.00	3.61	4.43
2026-03-23	ADCT	0.00	3.61	4.43
2026-03-24	ADCT	0.00	3.61	4.43
2026-03-25	ADCT	0.00	3.61	4.63
2026-03-26	ADCT	0.00	3.61	4.63
2026-03-27	ADCT	0.00	3.61	4.63
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.04

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

-0.2

Insider Transactions

Institutional Transactions

3.61

Beta

1.91

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

88.4

Max Drawdown 5-Year %

-98.5

Target Price

8.2

P/E

Forward P/E

PEG

P/S

5.8

P/B

P/Free Cash Flow

EPS

-1.2

Average EPS Est. Cur. Y

-0.81

EPS Next Y. (Est.)

-0.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-175.31

Relative Volume

1.26

Return on Equity vs Sector %

49.4

Return on Equity vs Industry %

65.7

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.27

EBIT Estimation

◆ ADCT Healthcare

$3.70

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

19/25

Volume

4/15

Valuation

9/20

TP/AR

2/10

Options

5/10

RSI

Range 1M

10.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

25/30

Estimates

2/20

Inst/Vol

8/15

Options

7/10

EPS Yr

28.6%

EPS NY

20.5%

52W%

73.9%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +121.6% upside

Quality

7/30

Valuation

16/30

Growth

20/25

Stability

7/10

LT Trend

0/5

Upside

+121.6%

Quality

ADC Therapeutics SA

Sector: Healthcare

Industry: Biotechnology

Employees: 188

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT

Latest News

—

Caricamento notizie per ADCT…

stock quote shares ADCT – Adc Therapeutics SA Stock Price stock today

news today ADCT – Adc Therapeutics SA stock forecast ,stock prediction 2023 2024 2025

marketwatch ADCT – Adc Therapeutics SA yahoo finance google finance

stock history ADCT – Adc Therapeutics SA invest stock market

stock prices ADCT premarket after hours

ticker ADCT fair value insiders trading

CS – Credit Suisse Group AG

UBS – UBS Group AG

UBS — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

0.27

Margin Of Safety %

Put/Call OI Ratio

1.27

EPS Next Q Diff

0.48

EPS Last/This Y

0.7

EPS This/Next Y

0.82

Price

36.4

Target Price

47.94

Analyst Recom

2.65

Performance Q

-22.9

Upside

126.9%

Beta

1.18

Ticker: UBS

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-02-27	UBS	41.4	2.00	2.27	81853
2026-03-02	UBS	40.88	2.01	2.07	82386
2026-03-03	UBS	39.69	2.01	2.30	83638
2026-03-04	UBS	39.74	2.02	0.62	84358
2026-03-05	UBS	39.26	2.00	0.92	84916
2026-03-06	UBS	38.44	1.95	10.83	83940
2026-03-09	UBS	38.65	2.04	1.02	87356
2026-03-10	UBS	38.83	2.03	1.35	88656
2026-03-11	UBS	38.88	2.02	0.38	89349
2026-03-12	UBS	37.51	1.97	1.19	90767
2026-03-13	UBS	37.51	1.97	1.22	90767
2026-03-17	UBS	37.97	1.79	0.67	95789
2026-03-18	UBS	37.39	1.66	0.69	102600
2026-03-19	UBS	37.36	1.59	1.29	104790
2026-03-20	UBS	36.74	1.49	0.15	108031
2026-03-23	UBS	37.54	1.49	1.09	100183
2026-03-24	UBS	37	1.48	0.77	101920
2026-03-25	UBS	38.09	1.45	0.14	103214
2026-03-26	UBS	37.27	1.26	8.97	110720
2026-03-27	UBS	36.4	1.27	0.42	114811
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-02-27	UBS	41.40	34.1	-	2.81
2026-03-02	UBS	40.87	34.1	-	2.81
2026-03-03	UBS	39.69	34.1	-	2.81
2026-03-04	UBS	39.74	34.1	-	2.81
2026-03-05	UBS	39.27	34.1	-	2.81
2026-03-06	UBS	38.43	34.1	-	2.81
2026-03-09	UBS	38.64	34.1	-	2.81
2026-03-10	UBS	38.83	34.1	-	2.81
2026-03-11	UBS	38.88	34.1	-	2.81
2026-03-12	UBS	37.49	34.1	-	2.81
2026-03-13	UBS	36.94	34.1	-	2.81
2026-03-17	UBS	37.97	34.1	-	3.16
2026-03-18	UBS	37.38	34.1	-	3.16
2026-03-19	UBS	37.35	34.1	-	3.16
2026-03-20	UBS	36.74	34.1	-	3.16
2026-03-23	UBS	37.54	34.1	-	3.16
2026-03-24	UBS	36.99	34.1	-	3.16
2026-03-25	UBS	38.09	34.1	-	3.16
2026-03-26	UBS	37.27	34.1	-	3.16
2026-03-27	UBS	36.40	34.1	-	3.16
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-02-27	UBS	0.00	-2.43	0.34
2026-03-02	UBS	0.00	-4.20	0.34
2026-03-03	UBS	0.00	-4.20	0.34
2026-03-04	UBS	0.00	-4.20	0.34
2026-03-05	UBS	0.00	-4.20	0.34
2026-03-06	UBS	0.00	-4.20	0.34
2026-03-09	UBS	0.00	-4.27	0.34
2026-03-10	UBS	0.00	-4.27	0.34
2026-03-11	UBS	0.00	-4.27	0.24
2026-03-12	UBS	0.00	-4.27	0.24
2026-03-13	UBS	0.00	-4.27	0.24
2026-03-17	UBS	0.00	-4.28	0.24
2026-03-18	UBS	0.00	-4.28	0.24
2026-03-19	UBS	0.00	-4.28	0.24
2026-03-20	UBS	0.00	-4.28	0.24
2026-03-23	UBS	0.00	-4.28	0.24
2026-03-24	UBS	0.00	-4.28	0.24
2026-03-25	UBS	0.00	-4.28	0.27
2026-03-26	UBS	0.00	-4.28	0.27
2026-03-27	UBS	0.00	-4.28	0.27
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.37

Avg. EPS Est. Current Quarter

0.8

Avg. EPS Est. Next Quarter

0.85

Insider Transactions

Institutional Transactions

-4.28

Beta

1.18

Average Sales Estimate Current Quarter

10231

Average Sales Estimate Next Quarter

10065

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

26.3

Max Drawdown 5-Year %

-32.5

Target Price

47.94

P/E

15.43

Forward P/E

9.17

PEG

0.38

P/S

1.43

P/B

1.25

P/Free Cash Flow

EPS

2.36

Average EPS Est. Cur. Y

3.16

EPS Next Y. (Est.)

3.98

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

9.84

Relative Volume

0.9

Return on Equity vs Sector %

-2.9

Return on Equity vs Industry %

-2.3

EPS 1 7Days Diff

0.4

EPS 1 30Days Diff

-0.03

EBIT Estimation

◆ UBS Financial

$36.40

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

15/25

Volume

7/15

Valuation

15/20

TP/AR

2/10

Options

2/10

RSI

33.7

Range 1M

1.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

17/30

Estimates

4/20

Inst/Vol

2/15

Options

6/10

EPS Yr

35.5%

EPS NY

24.2%

52W%

45.5%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +211% upside

Quality

4/30

Valuation

20/30

Growth

19/25

Stability

2/10

LT Trend

3/5

Upside

+211%

Quality

UBS Group AG Registered

Sector: Financial Services

Industry: Banks - Diversified

Employees: 103177

UBS Group AG operates as a wealth manager and bank worldwide. It operates through five segments: Global Wealth Management, Personal & Corporate Banking, Asset Management, Investment Bank, and Non-Core and Legacy. The Global Wealth Management segment offers financial services, advice, and solutions; investment management, estate planning, and corporate advice services; and wealth management and banking products and services to private wealth and institutional customers. Its Personal & Corporate Banking segment provides banking, retirement, financing, investments, and strategic transactions to private, corporate, and institutional customers through its branch network and digital channels in Switzerland. The Asset Management segment offers diversified asset management services. Its Investment Bank segment provides equities, foreign exchange, precious metals, research, advisory, and capital markets services to institutional, corporate, financial sponsor, and Global Wealth Management customers, as well as focused rates and credit platform. The company also offers lending products, such as securities-based lending, mortgages, structured products, and tailored solutions; collateralized lending residential and commercial real estate, primarily against securities, residential and commercial real estate, other real assets (such as ships and aircraft), private market and hedge fund interest; and unsecured lending. The company was formerly known as UBS AG and changed its name to UBS Group AG in December 2014. UBS Group AG was founded in 1862 and is headquartered in Zurich, Switzerland.

UBS

Latest News

—

Caricamento notizie per UBS…

stock quote shares UBS – UBS Group AG Stock Price stock today

news today UBS – UBS Group AG stock forecast ,stock prediction 2023 2024 2025

marketwatch UBS – UBS Group AG yahoo finance google finance

stock history UBS – UBS Group AG invest stock market

stock prices UBS premarket after hours

ticker UBS fair value insiders trading

STM – STMicroelectronics N.V.

STM — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

1.26

Margin Of Safety %

Put/Call OI Ratio

0.65

EPS Next Q Diff

0.11

EPS Last/This Y

0.97

EPS This/Next Y

0.72

Price

32.55

Target Price

35.97

Analyst Recom

2.19

Performance Q

24.58

Upside

-81.7%

Beta

1.52

Ticker: STM

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-02-27	STM	33.63	0.62	0.19	164083
2026-03-02	STM	33.63	0.64	0.22	162357
2026-03-03	STM	31.65	0.65	1.00	162766
2026-03-04	STM	33.37	0.70	0.29	167304
2026-03-05	STM	33.31	0.69	0.59	170724
2026-03-06	STM	31.36	0.69	0.13	172325
2026-03-09	STM	33.54	0.69	0.11	172443
2026-03-10	STM	33.55	0.64	0.05	180182
2026-03-11	STM	34.06	0.60	0.31	188934
2026-03-12	STM	33.26	0.59	0.19	194054
2026-03-13	STM	33.24	0.59	0.19	194054
2026-03-17	STM	33.78	0.57	0.21	207089
2026-03-18	STM	33.24	0.57	0.45	206885
2026-03-19	STM	32.41	0.59	0.09	208107
2026-03-20	STM	30.86	0.57	0.40	212806
2026-03-23	STM	31.67	0.63	1.55	170242
2026-03-24	STM	31.98	0.64	0.80	172696
2026-03-25	STM	33.51	0.65	0.17	175709
2026-03-26	STM	32.78	0.65	0.36	177912
2026-03-27	STM	32.56	0.65	0.28	178531
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-02-27	STM	33.63	160.9	772.5	1.18
2026-03-02	STM	33.51	160.9	99.7	1.16
2026-03-03	STM	31.63	160.9	342.3	1.16
2026-03-04	STM	33.38	160.9	432.1	1.16
2026-03-05	STM	33.31	160.9	415.2	1.16
2026-03-06	STM	31.36	160.9	359.8	1.16
2026-03-09	STM	33.52	160.9	491.9	1.16
2026-03-10	STM	33.55	160.9	438.6	1.16
2026-03-11	STM	34.06	160.9	393.4	1.16
2026-03-12	STM	33.26	160.9	374.6	1.12
2026-03-13	STM	32.87	160.9	374.8	1.12
2026-03-17	STM	33.79	160.9	373.1	1.12
2026-03-18	STM	33.24	160.9	357.6	1.12
2026-03-19	STM	32.41	160.9	336.0	1.12
2026-03-20	STM	30.86	160.9	339.0	1.12
2026-03-23	STM	31.66	160.9	382.1	1.12
2026-03-24	STM	31.95	160.9	391.8	1.12
2026-03-25	STM	33.41	160.9	412.4	1.16
2026-03-26	STM	32.92	160.9	357.8	1.16
2026-03-27	STM	32.55	160.9	362.7	1.16
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-02-27	STM	0	10.15	1.34
2026-03-02	STM	0	8.48	1.34
2026-03-03	STM	0	8.48	1.34
2026-03-04	STM	0	8.48	1.34
2026-03-05	STM	0	8.48	1.34
2026-03-06	STM	0	8.48	1.34
2026-03-09	STM	0	0.94	1.34
2026-03-10	STM	0	0.94	1.34
2026-03-11	STM	0	0.94	1.19
2026-03-12	STM	0	0.94	1.19
2026-03-13	STM	0	0.94	1.19
2026-03-17	STM	0	-0.33	1.19
2026-03-18	STM	0	-0.33	1.19
2026-03-19	STM	0	-0.33	1.19
2026-03-20	STM	0	-0.33	1.19
2026-03-23	STM	0	-1.69	1.19
2026-03-24	STM	0	-1.69	1.19
2026-03-25	STM	0	-1.69	1.26
2026-03-26	STM	0	-1.69	1.26
2026-03-27	STM	0	-1.69	1.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.11

Avg. EPS Est. Current Quarter

0.17

Avg. EPS Est. Next Quarter

0.22

Insider Transactions

Institutional Transactions

-1.69

Beta

1.52

Average Sales Estimate Current Quarter

3046

Average Sales Estimate Next Quarter

3159

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

41.7

Max Drawdown 5-Year %

-66.7

Target Price

35.97

P/E

187.88

Forward P/E

16.1

PEG

0.22

P/S

2.45

P/B

1.62

P/Free Cash Flow

703.15

EPS

0.17

Average EPS Est. Cur. Y

1.16

EPS Next Y. (Est.)

1.88

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

1.39

Relative Volume

0.99

Return on Equity vs Sector %

-52.8

Return on Equity vs Industry %

-55.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

362.7

◆ STM Technology

$32.54

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

21/25

Volume

7/15

Valuation

10/20

TP/AR

3/10

Options

5/10

RSI

Range 1M

45.9%

Sup Dist

0.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

18/30

Estimates

6/20

Inst/Vol

5/15

Options

8/10

EPS Yr

120.9%

EPS NY

72.6%

52W%

84.5%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +76% upside

Quality

5/30

Valuation

18/30

Growth

14/25

Stability

6/10

LT Trend

0/5

Upside

+76%

Quality

STMicroelectronics N.V.

Sector: Technology

Industry: Semiconductors

Employees: 49157

STMicroelectronics N.V., together with its subsidiaries, designs, develops, manufactures, and sells semiconductor products in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company operates through Analog products, MEMS and Sensors Group (AM&S); Power and Discrete products (P&D); Embedded Processing (EMP); and RF Products (D&RF) segments. It offers industrial application-specific integrated circuits (ASICs) and application-specific standard products (ASSPs); power management solutions; custom analog ICs, wireless charging solutions; galvanic isolated gate and LED drivers; converters, transistors, intelligent power switches, clocks and timers, comparators, and current-sense amplifiers; micro-electro-mechanical systems (MEMS) sensors, including accelerometers, gyroscopes, magnetic sensors, pressure, temperature, presence detection, biosensors, machine learning, and edge AI processing smart sensors, as well as thermal and piezoelectric actuators; and optical sensing solutions. The company also provides silicon MOSFETs, SiC MOSFETs, IGBTs, thyristors, rectifiers, and power modules and bipolar transistors; microcontrollers, and automotive microcontrollers and secured; radio frequency (RF) communications and ASICs; car infotainment products; ultra-wide band and radar systems; and Connected Security Products; and automotive driver assistance systems. It serves automotive, industrial, personal electronics and communications equipment, and computers and peripherals markets. STMicroelectronics N.V. was incorporated in 1987 and is headquartered in Schiphol, the Netherlands.

STM

Latest News

—

Caricamento notizie per STM…

stock quote shares STM – STMicroelectronics N.V. Stock Price stock today

news today STM – STMicroelectronics N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch STM – STMicroelectronics N.V. yahoo finance google finance

stock history STM – STMicroelectronics N.V. invest stock market

stock prices STM premarket after hours

ticker STM fair value insiders trading

No more stocks to show

ONC – BeOne Medicines Ltd ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ONC

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

AMRZ – Amrize Ltd

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: AMRZ

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y